logo

LENZ

LENZ Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.71 / 10
Netural

Comprehensive fundamental review scores 3.7/10, indicating weak fundamentals. Profit-MV and net income-revenue are favorable, yet Asset-MV and Revenue-MV are negative. Gross profit margin is high at 100%, but inventory turnover is elevated. Historical back-tests show mixed returns across metrics, with PB-ROE yielding 11.66% one-month returns but Asset-MV only 4.17%. This suggests limited operational efficiency and value, constraining upside potential.

Fundamental(3.71)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-2.64
Score1/3
Weight10.63%
1M Return5.63%
Inventory turnover ratio
Value47.88
Score3/3
Weight9.74%
1M Return5.89%
Gross profit margin (%)
Value100.00
Score1/3
Weight0.31%
1M Return0.22%
Profit-MV
Value0.47
Score2/3
Weight14.88%
1M Return7.95%
Net income-Revenue
Value-0.15
Score2/3
Weight15.08%
1M Return8.04%
PB-ROE
Value5.04
Score3/3
Weight22.38%
1M Return11.66%
Current assets turnover ratio
Value0.08
Score2/3
Weight2.64%
1M Return1.75%
Fixed assets turnover ratio
Value8.55
Score3/3
Weight2.25%
1M Return1.53%
Asset-MV
Value-0.51
Score0/3
Weight7.35%
1M Return4.17%
Cash-MV
Value-0.07
Score2/3
Weight14.74%
1M Return7.78%
Is LENZ fundamentally strong?
  • LENZ scores 3.71/10 on fundamentals and holds a Fair valuation at present. Backed by its -23.23% ROE, 0.00% net margin, -6.89 P/E ratio, 2.09 P/B ratio, and 85.26% earnings growth, these metrics solidify its Netural investment rating.